Table 1.
Trials (n)* | Women (n) | Deaths (n)† | Median years per woman (IQR) |
Woman-years by years since entry (thousands) |
||||
---|---|---|---|---|---|---|---|---|
<10 | 10–19 | ≥20 | Total | |||||
No anthracycline or taxane8, 11, 12, 17‡ | 4 | 918 | 315 | 7·0 (4·2–9·3) | 6·0 | 0·8 | 0·2 | 7·0 |
Anthracycline, no taxane9, 10, 14, 15, 16 | 5 | 2936 | 1163 | 10·2 (4·9–15·4) | 22·1 | 7·7 | <0·1 | 29·8 |
Anthracycline and taxane13 | 1 | 902 | 126 | 7·9 (5·0–10·7) | 6·5 | 0·5 | 0 | 7·0 |
Total | 10 | 4756 | 1604 | 8·6 (4·8–13·7) | 34·6 | 9·0 | 0·2 | 43·7 |
Data are missing for six small trials that randomised about 500 women, so they were not included in this analysis (appendix p 17).
Includes 1356 deaths with recurrence, 72 of unknown cause without recurrence, and 176 of known cause without recurrence.
In these trials, women allocated to the neoadjuvant group completed their chemotherapy after surgery.